MDD Clinical Trial
Official title:
Reducing Neural Perseveration Through Closed Loop Real Time fMRI Neurofeedback to Alleviate Depressive Symptoms
This study tests the efficacy of a new psychotherapeutic strategy for reducing negative attention bias (and therefore depression severity) in participants with MDD (60 in R61 phase and 80 in R33 Phase). This real-time fMRI neurofeedback therapy uses cloud-based pattern classification to decode a patient's attentional state and dynamically modulate task stimuli (in a closed loop) based on this state.
In both the R61and R33 phases we will compare cloud based real time fMRI feedback with placebo (sham feedback) in reducing negative attention bias and depressive symptoms. This study will be the first dose-finding test of real-time fMRI effect on negative attention bias. Measures include: Structured Clinical Interview for DSM-5 (SCID), Clinician-administered diagnostic exam, Montgomery Asberg Depression Rating Scale (MADRS), Clinician-administered scale used to assess the severity of depression, State-Trait Anxiety Inventory (STAI), Self-report questionnaire used to measure types of anxiety and mood symptoms, Mood and Anxiety Symptom Questionnaire (MASQ), Negative perseveration during a go/no-go task, Go/no-go task with overlaid face/scene stimuli; brain response triggers next stimulus, Negative gaze, Negative gaze collected in gaze data following each real time fMRI feedback session ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04482296 -
Effect of Zinc Supplementation on Depression in SSRI-treated Major Depressive Disorder Patients
|
N/A | |
| Recruiting |
NCT04071886 -
Effect of Short-Term Mindfulness-Based Training For Major Depression Disorder: An Eye-Tracking Study
|
N/A | |
| Completed |
NCT04076644 -
Maintenance Transcranial Magnetic Stimulation in Major Depressive Disorder
|
N/A | |
| Completed |
NCT05528315 -
SAD/MAD of ABX-002-1902 Investigating the Safety, Pharmacokinetics/Pharmacodynamics of in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT05437588 -
Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
|
N/A | |
| Recruiting |
NCT06095778 -
rTMS Therapy for Treatment-Resistant Depression With Different Targets Guided by pBFS
|
N/A | |
| Active, not recruiting |
NCT05657691 -
Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD)
|
Phase 2 | |
| Completed |
NCT02013609 -
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
|
Phase 3 | |
| Completed |
NCT02339285 -
Transcranial Alternating Current Stimulation for Major Depressive Disorder
|
N/A | |
| Recruiting |
NCT03971305 -
A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL
|
||
| Completed |
NCT01344733 -
A Non Interventional Study to Investigating the Ratio of Mis-diagnosed Bipolar Symptoms in Patient With Major Depressive Disorder (MDD)
|
N/A | |
| Completed |
NCT04268316 -
Virtual Reality Behavioral Activation: An Intervention for Major Depressive Disorder
|
N/A | |
| Active, not recruiting |
NCT01557946 -
Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression
|
Phase 2 | |
| Recruiting |
NCT01501812 -
Evaluation of Generalization Paradigm Patterns Among Different Psychiatric Disorders
|
N/A | |
| Completed |
NCT04880460 -
Effect of Magnesium Supplementation in Selective Serotonin Reuptake Inhibitors Treated Major Depressive Disorder Patients
|
Phase 2 | |
| Completed |
NCT04226352 -
Three Dosing Regimens of Dextromethorphan (DXM) Reportedly Used in Major Depressive Disorder
|
Phase 1 | |
| Recruiting |
NCT03754712 -
Effect of Vitamin D Administration Along With SSRIs in Patients With Major Depressive Disorder
|
N/A | |
| Recruiting |
NCT02669030 -
A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia
|
Phase 4 | |
| Completed |
NCT03994081 -
Mechanism of Action of tACS for the Treatment of MDD
|
N/A | |
| Completed |
NCT01152554 -
A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder
|
Phase 3 |